Kevin Mitchell
Research Subjects
Research Interests
Kevin Mitchell has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Abhay Lodha
Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Canada
1 shared publication - Alexander Lyttle
Department of Paediatrics, University of Calgary, Alberta Children’s Hospital, Calgary, Canada
1 shared publication - Harish Amin
Section of Neonatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
1 shared publication - Helen Lee Robertson
Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
1 shared publication - Huma Shaireen
Section of Neonatology, Department of Paediatrics, University of Calgary, Foothills Medical Centre, Calgary, Canada
1 shared publication Justin Lui
Faculty of Medicine, University of Calgary, Calgary, Alberta
1 shared publication
Latest Publications
- Open Access
- 1 March 2015
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 20 (2) , 69-70
Case 1: A two-year-old boy with fever and widespread vesicular lesions
A previously healthy two-year-old boy presented to the emergency department at the authors' hospital following a two-day history of fever, oral sores and widespread vesicular lesions with increased irritability, decreased oral intake and persistent fever over the course of the day.
- 1 March 2015
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 20 (2) , 69-70
Open AccessCase 1: A two-year-old boy with fever and widespread vesicular lesions
A previously healthy two-year-old boy presented to the emergency department at the authors' hospital following a two-day history of fever, oral sores and widespread vesicular lesions with increased irritability, decreased oral intake and persistent fever over the course of the day.
- Open Access
- 10 September 2014
- Published by Springer Nature in BMC Pediatrics
- Vol. 14 (1) , 1-10
Arginine supplementation in prevention of necrotizing enterocolitis in the premature infant: an updated systematic review
Hypoxic-ischemic injury is thought to play a significant role in necrotizing enterocolitis (NEC). Nitric Oxide (NO) is the principal inhibitory neurotransmitter in the gut and is involved in regulation of mucosal blood flow and maintenance of mucosal integrity. NO is synthesized from L-arginine by NO synthases. Our primary objective was to determine the effectiveness of supplemental L-arginine versus placebo in prevention of NEC in preterm infants ≤ 34 weeks gestational age by systematic review of published randomized controlled trials (RCTs). This review included RCTs in which L-arginine was administered as a supplement to neonates to prevent NEC. Searches were conducted in OVID MEDLINE, EMBASE, PubMed, and CINAHL from their dates of inception to July, 2014. Inclusion criteria were informed parental consent, neonates born at ≤ 34 weeks gestation, and birth weight ≤ 1500 g. Exclusion criteria included neonates with severe congenital anomalies and inborn errors of metabolism. Incidence of NEC was the primary outcome measure. Whole data were analyzed by RevMan 5.1 (Update Software, Oxford, UK). Outcome data were analyzed to determine risk ratios, number needed to treat, confidence intervals, and test for overall effect. Two trials including 425 neonates were eligible for this review. Of these, 235 neonates were included in the study. L-arginine had a 59% reduction in the incidence of stage II and III NEC (RR 0.41, 95% CI 0.20 to 0.85, NNT = 9) compared with placebo (P = 0.02). A similar finding was identified for all stages of NEC (60% reduction, RR 0.40, 95% CI 0.23 to 0.69, NNT = 5) (P = 0.001). At age 3 yrs, there was no significant difference between the 2 groups in terms of any neurodevelopmental disability (RR 0.65; 95% CI 0.23-1.83, P = 0.41). L-arginine supplementation appears to be protective in prevention of NEC in preterm infants and without any significant impact on neurodevelopmental outcomes at 36 months of corrected age. With the addition of the results of one more study to the literature, an intriguing role for L-arginine supplementation continues to gain support. However, large multi-centre RCTs are needed before this can become common practice.
- 10 September 2014
- Published by Springer Nature in BMC Pediatrics
- Vol. 14 (1) , 1-10
Open AccessArginine supplementation in prevention of necrotizing enterocolitis in the premature infant: an updated systematic review
Hypoxic-ischemic injury is thought to play a significant role in necrotizing enterocolitis (NEC). Nitric Oxide (NO) is the principal inhibitory neurotransmitter in the gut and is involved in regulation of mucosal blood flow and maintenance of mucosal integrity. NO is synthesized from L-arginine by NO synthases. Our primary objective was to determine the effectiveness of supplemental L-arginine versus placebo in prevention of NEC in preterm infants ≤ 34 weeks gestational age by systematic review of published randomized controlled trials (RCTs). This review included RCTs in which L-arginine was administered as a supplement to neonates to prevent NEC. Searches were conducted in OVID MEDLINE, EMBASE, PubMed, and CINAHL from their dates of inception to July, 2014. Inclusion criteria were informed parental consent, neonates born at ≤ 34 weeks gestation, and birth weight ≤ 1500 g. Exclusion criteria included neonates with severe congenital anomalies and inborn errors of metabolism. Incidence of NEC was the primary outcome measure. Whole data were analyzed by RevMan 5.1 (Update Software, Oxford, UK). Outcome data were analyzed to determine risk ratios, number needed to treat, confidence intervals, and test for overall effect. Two trials including 425 neonates were eligible for this review. Of these, 235 neonates were included in the study. L-arginine had a 59% reduction in the incidence of stage II and III NEC (RR 0.41, 95% CI 0.20 to 0.85, NNT = 9) compared with placebo (P = 0.02). A similar finding was identified for all stages of NEC (60% reduction, RR 0.40, 95% CI 0.23 to 0.69, NNT = 5) (P = 0.001). At age 3 yrs, there was no significant difference between the 2 groups in terms of any neurodevelopmental disability (RR 0.65; 95% CI 0.23-1.83, P = 0.41). L-arginine supplementation appears to be protective in prevention of NEC in preterm infants and without any significant impact on neurodevelopmental outcomes at 36 months of corrected age. With the addition of the results of one more study to the literature, an intriguing role for L-arginine supplementation continues to gain support. However, large multi-centre RCTs are needed before this can become common practice.